The Lancet Diabetes & Endocrinology最新文献

{"title":"An important new data source for obesity trends in England.","authors":"Martin Gulliford","doi":"10.1016/S2213-8587(26)00130-0","DOIUrl":"10.1016/S2213-8587(26)00130-0","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"705-706"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight management in China: integrating mental health into routine obesity care.","authors":"Qingqing Yin, Jingliang Zhang, Renjun Lv, Ziqian Zhao, Ziying Jiang, Lin Lu","doi":"10.1016/S2213-8587(26)00156-7","DOIUrl":"10.1016/S2213-8587(26)00156-7","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"707-708"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148377685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Goal-directed osteoporosis treatment: are bone mineral density targets valid?","authors":"Ian R Reid","doi":"10.1016/S2213-8587(26)00123-3","DOIUrl":"10.1016/S2213-8587(26)00123-3","url":null,"abstract":"<p><p>Over the last decade, goal-directed management of osteoporosis has been developed as a concept. In 2024, a working group of the American Society for Bone and Mineral Research (ASBMR) determined that this concept should include specific bone mineral density (BMD) targets during treatment, to ensure optimal fracture risk reduction. Two observations were key to this recommendation: that higher on-treatment BMDs are associated with lower fracture risks in several studies, and that, in a meta-regression of individual clinical trials, agents producing larger increases in BMD also produced greater reduction in fracture risk. However, the inferences drawn from these studies might be unsound. First, on-treatment BMD is the sum of baseline BMD and its change on therapy. In trials in which these variables have both been considered, it was found that the influence of on-treatment BMD is substantially a reflection of the effect of baseline BMD on fracture risk rather than an effect of on-treatment BMD change. Second, the meta-regression findings are heavily dependent on the inclusion of less effective treatments in the analysis. Among more effective antiresorptives, no such relationship is seen. For example, although denosumab has greater effects on BMD than zoledronate, these agents have similar anti-fracture efficacy in trials. Therefore, a key conclusion of the treat-to-BMD-target framework-that denosumab is needed for many patients to reach their BMD targets-has no clinical trial support, suggesting the framework is flawed. Thus, use of BMD treatment targets in osteoporosis management is not supported by available evidence, so the frequent BMD measurements required by the treat-to-target framework will increase costs without demonstrable benefit.</p>","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"787-792"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148413400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Energy drink ban: putting children's health first.","authors":"The Lancet Diabetes Endocrinology","doi":"10.1016/S2213-8587(26)00195-6","DOIUrl":"10.1016/S2213-8587(26)00195-6","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"703"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soaring GLP-1 receptor agonist use.","authors":"The Lancet Diabetes Endocrinology","doi":"10.1016/S2213-8587(26)00194-4","DOIUrl":"10.1016/S2213-8587(26)00194-4","url":null,"abstract":"","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"703"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148622225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-population trends in obesity across dimensions of inequality in England, 2019-25: a retrospective, longitudinal cohort study of 54 million adults.","authors":"Robert A Fletcher, Nathalie Conrad, Patrick Rockenschaub, Stelios Boulitsakis Logothetis, Brendon L Neuen, Fionna Chalmers, Mayank Dalakoti, Elena Raffetti, Spiros Denaxas, Kamlesh Khunti, I Sadaf Farooqi, Clare Arnott, Emanuele Di Angelantonio, John Danesh, Reecha Sofat, Naveed Sattar, Angela M Wood","doi":"10.1016/S2213-8587(26)00120-8","DOIUrl":"10.1016/S2213-8587(26)00120-8","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Obesity is one of the 21st century's greatest public health challenges. Evidence on how inequalities intersect to shape the obesity burden is scarce, particularly since the COVID-19 pandemic. We aimed to investigate trends in the incidence and prevalence of obesity among adults in England, and to examine variation by age, sex, socioeconomic status, ethnicity, and geographical region.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this retrospective, longitudinal cohort study, we analysed whole-population, individual-level, anonymised, electronic health records with life-course data on the entire population of adults aged 18-99 years in England, accessed via the National Health Service England Secure Data Environment. We estimated age- and sex-standardised incidence and prevalence rates of obesity (BMI ≥30·0 kg/m&lt;sup&gt;2&lt;/sup&gt; or clinician-assigned diagnosis) from 2019 to 2025 and used negative binomial regression to examine trends by age, sex, socioeconomic status, ethnicity, and geographical region (defined using middle layer super output areas: neighbourhood-level units comprised of 5000 to 15 000 individuals).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between Nov 1, 2019, and April 30, 2025, we identified 54 892 390 adults with records in the National Health Service England Secure Data Environment. 4 131 555 people had a first presentation of obesity during the study period, of whom 2 278 485 (55·1%) were women and 1 853 070 (44·9%) were men. 3 106 740 (75·2%) of individuals were White, 482 690 (11·7%) were Asian or Asian British, and 291 920 (7·1%) were Black, Black British, Caribbean, or African. The median age at first presentation of obesity was 43 years (IQR 31-58), and mean BMI was 33·4 kg/m&lt;sup&gt;2&lt;/sup&gt; (SD 10·7). The overall age- and sex-standardised incidence of first-recorded obesity was 22 per 1000 person-years (95% CI 22-22) and increased by 4% over the study period (incidence rate ratio [IRR] 2024-2025 vs 2019-2020 1·04, 95% CI 1·01-1·07), with marked variation across subgroups. The steepest increases over time occurred in those aged 20-29 years (IRR 1·16, 95% CI 1·08-1·25) and in those aged 30-39 years (1·19, 1·13-1·25). Obesity incidence was 35% greater in the most socioeconomically deprived quintile compared with the least deprived quintile (IRR 1·35, 95% CI 1·28-1·42), with greater disparities in women (1·54, 1·45-1·64), particularly Asian women (1·94, 1·86-2·02). By 2025, overall obesity prevalence reached 30·3%, rising from 26·3% at the start of the study. There was considerable variation in obesity prevalence by age, sex, socioeconomic status, and ethnicity, ranging from 4·3% in the least socioeconomically deprived White men aged 18-19 years to 66·1% in the most deprived Black women aged 60-69 years, which was nearly double that in the least-deprived White women in the same age group (60-69 years; 34·5%). Geographical disparities were striking, with prevalence varying between 8·5% and 48·1% (a nearly 6-fold differen","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"740-753"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148320095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement.","authors":"Laurence J Dobbie, Liisa Tolvanen, Daniela Alves, Jennifer L Baker, Natalie S Bez, Susie Birney, Leonie H Bogl, Adrian Brown, Monica Bullo, Ken Clare, Emma L Duncan, Ellen Govers, Vicki Mooney, Hilda Mulrooney, Daniela Ojeda Mercado, Grace O'Malley, Jean-Michel Oppert, Toby Pillinger, Wineke Remijnse, Emma Shuttlewood, Maria Wakolbinger, Euan Woodward, Volkan D Yumuk, Maria Hassapidou, Andreea Ciudin, Barbara McGowan","doi":"10.1016/S2213-8587(26)00122-1","DOIUrl":"10.1016/S2213-8587(26)00122-1","url":null,"abstract":"<p><p>Incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1-GIP receptor agonists, have transformed obesity management, producing substantial weight loss and cardiometabolic benefits, with potential improvements in obesity-related complications, physical function, quality of life, and psychological wellbeing for many individuals. However, reduced appetite, rapid weight loss, gastrointestinal adverse effects, and changes in eating behaviour might create nutritional, functional, or psychological risks in some individuals. This EASO-EFAD-ECPO Consensus Statement outlines pragmatic nutritional, functional, and psychological considerations during incretin-based therapy treatment. We synthesise evidence on medical nutrition therapy, including protein targets during weight loss, dietary quality, and mitigation of gastrointestinal adverse events. We discuss pragmatic approaches that could help support preservation of fat-free mass and physical function during weight loss, including adequate protein intake and progressive resistance exercise. We emphasise the psychological and identity-related challenges during incretin-based therapy, including shifts in food reward, coping, and social connection, and recommend psychological screening, with integrated support where needed. We propose pragmatic monitoring during weight loss, including diet quality, micronutrient risk, and functional measures, with body-composition assessment where indicated. We suggest approaches to address disparities in access and adherence to ensure equity. We discuss the importance of shared decision making with the patient in decisions to start, up-titrate, delay, pause, down-titrate, or discontinue incretin-based therapies, considering the physical and psychological risks of treating versus not treating. Finally, we identify future research priorities, including longitudinal research on micronutrient status, macronutrient requirements, changes in dietary patterns and food choices, musculoskeletal outcomes, unique dosing schedules, and post-cessation maintenance to optimise safety, efficacy, and the patient experience.</p>","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"754-777"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148413441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.","authors":"Erik Kadesjö, Jonas Söderling, Anders Hviid, Viktor Wintzell, Henrik Svanström, Björn Eliasson, Soffia Gudbjörnsdóttir, Mads Melbye, Kristian Hveem, Christian Jonasson, Daniel P Andersson, Björn Pasternak, Peter Ueda","doi":"10.1016/S2213-8587(26)00162-2","DOIUrl":"https://doi.org/10.1016/S2213-8587(26)00162-2","url":null,"abstract":"<p><strong>Background: </strong>SGLT2 inhibitors increase the risk of ketoacidosis, but data from routine clinical practice are scarce. We used nationwide registers with the aim of assessing the incidence, risk factors, and prognosis of ketoacidosis during SGLT2 inhibitor treatment in patients with type 2 diabetes.</p><p><strong>Methods: </strong>In this cohort and nested case-control study we used data from three Scandinavian countries. In a cohort of SGLT2 inhibitor-treatment episodes among patients with type 2 diabetes aged at least 18 years in Sweden, Denmark, and Norway, we estimated ketoacidosis incidence. Using a nested case-control design (matched on age, sex, region of birth, calendar time, and time since treatment initiation), we assessed risk factors and precipitating or co-occurring events. Changes in diabetes medications were evaluated.</p><p><strong>Findings: </strong>The study period was Jan 1, 2013, to Dec 31, 2021, in Denmark and Sweden, and Jan 1, 2013, to Dec 31, 2022, in Norway. We included 322 597 treatment episodes among 282 282 patients with type 2 diabetes (mean age 63 years, 116 521 [36·1%] of 322 597 women). During a median (IQR) follow-up of 1·3 (0·7-2·8) years, 1452 ketoacidosis events occurred (incidence 2·43 per 1000 person-years). Although highest shortly after initiation, risk persisted throughout follow-up. Strong risk factors included high HbA_1c (≥83 vs ≤52 mmol/mol: odds ratio [OR] 15·37 [95% CI 11·50-20·53]), malnutrition (OR 10·54 [7·32-15·18]), previous ketoacidosis (OR 10·40 [7·09-15·24]), low BMI (<20 kg/m²vs 20 to <25 kg/m²: OR 9·98 [5·68-17·53]), and recent hypoglycaemia (OR 5·22 [2·60-10·49]). Infection was the most common precipitating or co-occurring event (454 [31·8%] of 1428 vs 862 [6·1%] of 14 233 for ketoacidosis cases vs controls; OR 7·60 [6·62-8·71]). The strongest associations were observed for alcohol intoxication, acute renal events, acute abdomen, stroke, and major surgery, although associations for some transient exposures, particularly milder conditions, might have been overestimated because of under-registration among controls. Exploratory analyses suggested that the observed associations were largely general to patients with type 2 diabetes rather than specific to SGLT2 inhibitor use. At 1 year after ketoacidosis, 211 (25·1%) of 842 remained on SGLT2 inhibitors and insulin use increased from 269 (31·9%) of 842 to 615 (73·0%) of 842.</p><p><strong>Interpretation: </strong>Ketoacidosis risk with SGLT2 inhibitors varies greatly by patient characteristics and is not confined to early in treatment. Risk should be assessed throughout treatment, and patients should be instructed to pause treatment during acute illness and stress.</p><p><strong>Funding: </strong>Region Stockholm, Swedish Society of Medicine, Karolinska Institutet.</p>","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":""},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittent fasting to treat diabetes: time to update clinical practice guidelines.","authors":"Krista A Varady, Lisa S Chow, Courtney M Peterson","doi":"10.1016/S2213-8587(26)00119-1","DOIUrl":"10.1016/S2213-8587(26)00119-1","url":null,"abstract":"<p><p>Intermittent fasting is now the third most commonly practiced diet in the USA. Yet, despite more than 225 clinical trials-including nearly 40 in patients with diabetes or prediabetes-intermittent fasting has not yet been recommended as part of the American Diabetes Association (ADA) Standards of Care or the International Diabetes Federation (IDF) Global Clinical Practice Recommendations. In this Personal View, we start by synthesising evidence from trials in patients with type 2 diabetes, type 1 diabetes, prediabetes, and gestational diabetes. In adults with type 2 diabetes, diverse types of intermittent fasting, such as time-restricted eating, the 5:2 diet, and the fasting mimicking diet, reduce HbA_1c (typically by 0·3-1·2%), fasting glucose, 24-h glucose, and bodyweight relative to usual eating patterns. Moreover, intermittent fasting is as effective as calorie restriction for improving glycaemic control and does not increase the risk of hypoglycaemia when medications are adjusted using simple rules. Intermittent fasting might also reduce glycaemia in adults with prediabetes, whereas there are insufficient data to recommend its use in people with type 1 or gestational diabetes. Therefore, we argue that the evidence base has sufficiently matured to warrant including intermittent fasting in clinical practice guidelines as one of several evidence-based lifestyle options for type 2 diabetes. We also provide practical guidance for clinicians on prescribing intermittent fasting and safely managing people with diabetes.</p>","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"778-786"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13469085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial.","authors":"Jing Luo, Sylvia Kehlenbrink, Chung-Chou H Chang, Christina M Lalama, Jill Kirsch, Éimhín Ansbro, Margaret L Prust, Alana Garvin, Bedowra Zabeen, Edna Majaliwa, Kaushik Ramaiya, Neema Kayange, Abigail Foulds, Ajmina Hasan Flabe, Renatus Fabiano Nyarubamba, Bruce L Rollman, Graham D Ogle","doi":"10.1016/S2213-8587(26)00097-5","DOIUrl":"10.1016/S2213-8587(26)00097-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Human insulins including intermediate-acting human insulin (ie, isophane insulin) remain widely used for children and young people with type 1 diabetes, especially in low-resource settings. We aimed to assess whether insulin glargine reduces the risk of serious hypoglycaemia or improves time in range when compared against human isophane insulin among children and young people with type 1 diabetes in low-income and middle-income countries.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;HumAn-1 was a randomised, open label, parallel-group trial conducted at one site in Bangladesh and two sites in Tanzania. Participants aged 7-25 years with a clinical diagnosis of type 1 diabetes were randomly assigned (1:1) to receive insulin glargine (Basaglar, Eli Lilly, Indianapolis, IN, USA) or to continue usual care (ie, isophane insulin or premixed 70/30) for basal insulin coverage. Insulin glargine was administered subcutaneously, usually before bedtime. Isophane insulin or premixed 70/30 was administered once or twice per day, at the discretion of the treating clinician. Doses varied by participant. Randomisation was performed centrally and stratified by site. The coprimary outcomes, measured using blinded continuous glucose monitors at 6 months, were time in very low range (&lt;3 mmol/L or 54 mg/dL) and time in target range (3·9 mmol/L to 10·0 mmol/L or 70 mg/dL to 180 mg/dL). The primary analysis was done for the overall intention-to-treat (ITT) population. The safety population included all participants who received at least one dose of study treatment and was analysed according to the treatment actually received. In this study, all participants received at least one dose of their randomly assigned intervention (ie, the ITT population is the same as the safety population). This trial is registered with ClinicalTrials.gov (NCT05614089).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Between March 1 and Dec 19, 2023, we assessed 426 children and young people for eligibility. Of these, 400 (94%) were randomly assigned to receive either glargine (n=199) or usual care (n=201). At 6 months, the mean time in very low range was 3·6% (SD 5·6) in the glargine group and 3·4% (4·3) in the usual care group. After adjustment for prespecified baseline covariates, the adjusted mean difference was 0·22% (97·5% CI -0·83 to 1·27, p=0·63). The mean time in target range was 40·5% (SD 18·4) for glargine and 38·1% (18·1) for usual care. The adjusted mean difference was 0·55% (97·5% CI -2·78 to 3·89, p=0·71). Serious adverse events (SAEs) were uncommon, with a total of six SAEs among five (3%) of 199 participants in the glargine group and 14 SAEs among 13 (6%) of 201 participants in the usual care group.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;At 6 months, children and young people with type 1 diabetes living in low-resource settings randomly assigned to glargine had no evidence of effects on time in very low range and time in target range compared with those assigned to usual c","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":" ","pages":"727-739"},"PeriodicalIF":36.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148399676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}